— Know what they know.
Not Investment Advice

BNGO

Bionano Genomics, Inc.
1W: +7.1% 1M: +7.1% 3M: -23.6% YTD: -24.5% 1Y: -63.6% 3Y: -99.8% 5Y: -100.0%
$1.20
+0.02 (+1.69%)
After Hours: $1.15 (-0.05, -4.17%)
NASDAQ · Healthcare · Medical - Diagnostics & Research · $3.9M · Alpha Radar Sell · Power 44
Smart Money Score
Moderate 50
Insider
Congress
ETF Holdings
Key Statistics
Market Cap$3.9M
52W Range1.06-5.5
Volume579,901
Avg Volume187,771
Beta1.68
Dividend
Analyst Ratings
4 Buy 3 Hold 0 Sell
Consensus Buy
Company Info
CEORobert Erik Holmlin
Employees98
SectorHealthcare
IndustryMedical - Diagnostics & Research
IPO Date2018-08-21
9540 Towne Centre Drive
San Diego, CA 92121
US
858 888 7600
About Bionano Genomics, Inc.

Bionano Genomics, Inc. provides genome analysis software solutions. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight. The company also provides Saphyr and Bionano compute servers; and NxClinical which offers one system for analysis and interpretation of genomic variants from microarray and next-generation sequencing data for cytogenetics and molecular genetics. In addition, it offers testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; EpiPanelDx PLUS, a genetic testing panel for patients who have experienced seizures, infantile spasms, encephalopathy, or febrile seizures; PGx test, which identifies over 60 alleles in 11 genes. The company was founded in 2003 and is headquartered in San Diego, California.

Recent Insider Trades

NameTypeSharesPriceDate
Chaubey Alka F-InKind 18 $1.10 2026-02-17
Adamchak Mark F-InKind 3 $1.10 2026-02-17
Dixon Jonathan V. F-InKind 6 $1.10 2026-02-17
OLDAKOWSKI MARK F-InKind 20 $1.10 2026-02-17
Holmlin R. Erik F-InKind 51 $1.10 2026-02-17

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms